For help on how to get the results you want, see our search tips.
1738 results
Categories
Human Remove Human filter
Orphan designation status
Positive Remove Positive filter
-
List item
Orphan designation: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate (fedratinib) for: Treatment of post-polycythaemia vera myelofibrosis (updated)
Date of first decision: 26/11/2010, Positive, Last updated: 03/03/2021 -
List item
Orphan designation: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate (fedratinib) for: Treatment of post-essential thrombocythaemia myelofibrosis (updated)
Date of first decision: 26/11/2010, Positive, Last updated: 03/03/2021 -
List item
Orphan designation: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate (fedratinib) for: Treatment of primary myelofibrosis (updated)
Date of first decision: 01/10/2010, Positive, Last updated: 03/03/2021 -
List item
Orphan designation: (R)-1-[1-(4-acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea (ceclazepide) for: Treatment of gastro-entero-pancreatic neuroendocrine tumours (updated)
Date of first decision: 14/12/2015, Positive, Last updated: 02/03/2021 -
List item
Orphan designation: R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (netazepide) for: Treatment of gastric carcinoid (updated)
Date of first decision: 14/06/2007, Positive, Last updated: 02/03/2021 -
List item
Orphan designation: N-(4-(1-cyanocyclopentyl)phenyl)-2-(4-pyridinylmethyl)amino-3-pyridinecarboxamide methanesulfonate for: Treatment of gastric cancer (updated)
Date of first decision: 27/02/2017, Positive, Last updated: 02/03/2021 -
List item
Orphan designation: N-acetylgalactosamine-conjugated synthetic double-stranded oligomer specific to serpin family A member 1 gene for: Treatment of congenital alpha-1 antitrypsin deficiency (updated)
Date of first decision: 31/07/2018, Positive, Last updated: 02/03/2021 -
List item
Orphan designation: Tadekinig alfa for: Treatment of haemophagocytic lymphohistiocytosis (updated)
Date of first decision: 14/10/2016, Positive, Last updated: 19/02/2021 -
List item
Orphan designation: Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept) for: Treatment of beta thalassaemia intermedia and major (updated)
Date of first decision: 29/07/2014, Positive, Last updated: 18/02/2021 -
List item
Orphan designation: Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept) for: Treatment of myelodysplastic syndromes (updated)
Date of first decision: 22/08/2014, Positive, Last updated: 18/02/2021 -
List item
Orphan designation: Luspatercept for: Treatment of myelofibrosis (updated)
Date of first decision: 28/02/2020, Positive, Last updated: 18/02/2021 -
List item
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) for: Treatment of spinal muscular atrophy (updated)
Date of first decision: 14/12/2018, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel) for: Treatment of diffuse large B-cell lymphoma (updated)
Date of first decision: 17/07/2017, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel) for: Treatment of follicular lymphoma (updated)
Date of first decision: 25/05/2018, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Lisocabtagene maraleucel for: Treatment of primary mediastinal large B-cell lymphoma (updated)
Date of first decision: 19/11/2018, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-hydroxy-,15,15'-diester with N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-N6-carboxy-L-lysinamide cyclic (2.fwdarw.12)-(disulfide); where two identical synthetic peptide domains are covalently linked at the ends of the polyethylene glycol chain (pegcetacoplan) for: Treatment of C3 glomerulopathy
Date of first decision: 21/08/2019, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione for: Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes
Date of first decision: 12/12/2017, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: ciclosporin for: Treatment of moderate and severe closed traumatic brain injury
Date of first decision: 01/10/2010, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: 2-Hydroxyoleic acid for: Treatment of glioma
Date of first decision: 27/10/2011, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: Oxalobacter formigenes strain HC-1 for: Treatment of primary hyperoxaluria
Date of first decision: 17/02/2006, Positive, Last updated: 02/02/2021 -
List item
Orphan designation: Oxalobacter formigenes strain HC-1 for: Treatment of short bowel syndrome
Date of first decision: 15/10/2014, Positive, Last updated: 02/02/2021 -
List item
Orphan designation: Somapacitan for: Treatment of growth hormone deficiency
Date of first decision: 24/08/2018, Positive, Last updated: 01/02/2021 -
List item
Orphan designation: pemigatinib for: Treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK
Date of first decision: 17/10/2019, Positive, Last updated: 01/02/2021 -
List item
Orphan designation: Clofazimine for: Treatment of nontuberculous mycobacterial lung disease
Date of first decision: 21/08/2019, Positive, Last updated: 28/01/2021 -
List item
Orphan designation: Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (KTE-X19) for: Treatment of mantle cell lymphoma
Date of first decision: 13/11/2019, Positive, Last updated: 25/01/2021